About us
At Future Live, we believe in an approach that integrates scientific research with a genuine focus on people’s well-being.
Since 2012, we have been dedicated to the development of nutraceutical supplements and innovative health solutions, with a constant commitment to quality, efficacy, and safety.
Today, thanks to the trust of physicians and patients, we are a recognized reference in the urological, gynecological, and nephrological fields, supported by an increasingly solid medical information network and a growing presence in the digital sector.
Our goal is simple yet ambitious: to improve people’s quality of life, every day.
OUR HISTORY
Since its foundation, Future Live has turned its expertise into a path of continuous growth.
Each milestone achieved represents a step forward in our commitment to delivering effective solutions aligned with today’s needs.
2012
Foundation of Future Live
2013
Acquisition of the Cal-Car and Cal-Ace brands
2014
Launch of Solvhoren Retard
2015
Launch of 5AlfaProst
2016
Launch of Enzuryl Cist
Launch of Solvhoren Bustine
First clinical study on FeRNApyd (acute setting)
2017
Launch of Enflog 360
Launch of FeRNApyd
2018
Launch of Decand
2019
Launch of Pealgyl
2022
Launch of Enflog Gel Vaginale
Start of the second clinical study on FeRNApyd
2023
Completion of the second clinical study on FeRNApyd
Filing of Future Live’s first patent
2024
Launch of Enzuryl D-Mannosio
2025
Granting of Future Live’s first patent
2026
Publication of the second clinical study on FeRNApyd
Launch of a new product
